Product Description
Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Apadenoson)
Mechanisms of Action: ADORA2 Agonist
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myocardial Ischemia|Coronary Artery Disease
Phase 2: Coronary Artery Disease|Myocardial Ischemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ASPECT-2 | P3 |
Completed |
Coronary Artery Disease |
2012-04-18 |
2022-03-13 |
Treatments |
|
| ASPECT2 | P3 |
Terminated |
Coronary Artery Disease|Myocardial Ischemia |
2012-04-01 |
2019-03-19 |
Treatments |
|
| ASPECT | P3 |
Terminated |
Coronary Artery Disease|Myocardial Ischemia |
2012-04-01 |
2019-03-19 |
Treatments |
|
| BMS068645-305 | P3 |
Terminated |
Coronary Artery Disease|Myocardial Ischemia |
2006-11-01 |
2019-03-21 |
Treatments |
|
| BMS068645-203 | P2 |
Terminated |
Coronary Artery Disease|Myocardial Ischemia |
2006-03-01 |
2019-03-21 |
Treatments |
|
| BMS068645-302 | P3 |
Terminated |
Myocardial Ischemia|Coronary Artery Disease |
2006-03-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|